Dendreon Corporation Announces Promotion of Robert M. Hershberg to Senior Vice President and Chief Medical Officer.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--Jan. 8, 2004 Dendreon Corporation (Nasdaq:DNDN) announced today that Robert M. Hershberg M.D., Ph.D., has been promoted to senior vice president and chief medical officer. In his new position, Hershberg will oversee the clinical, regulatory and quality operations of the Company. Hershberg joined Dendreon in October of 2003 from Corixa Corporation (NASDAQ:CRXA), where he had most recently served as vice president of medical genetics medical genetics n. The study of the etiology, pathogenesis, and natural history of diseases and disorders that are at least partially genetic in origin. . Hershberg brings a range of industry experience in clinical development, including strategic development in oncology. Prior to joining Corixa in 2000, Hershberg was an assistant professor in the Department of Medicine and associate physician at Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. , Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , Boston, Mass. He received his M.D. from the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. and his Ph.D. from The Salk Institute. "Rob's expertise in clinical development along with his passion and drive to bring new treatment options to market will be helpful to Dendreon in our late-stage development efforts for Provenge(R) and our other promising programs," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Rob's contributions have already had a significant impact on the Company, and his expanded responsibilities will allow him the opportunity to contribute more broadly to our operations." Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge, is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the potential treatment of androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. independent prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing , small molecule and prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include reliance on key employees, especially senior management, risks related to Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the results of a clinical trial, including Phase 3 trials of Provenge, will not support applying for or approval of a biologics license by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , the risks associated with the preclinical and clinical development of our product candidates, the risk that clinical trials may be suspended or terminated because of unacceptable health risks or for other reasons, and the risks that our competitors may develop products that are safer, more effective or reach the market sooner than our product candidates, the uncertainty of Dendreon's future access to capital, the risk that Dendreon may not secure or maintain relationships with collaborators, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion